Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Honghong Zhou

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
The Lancet. Infectious Diseases|March 22, 2024
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trialAvika Dixit, Richard Bennett, Kashif Ali, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
Nature Medicine|February 11, 2022
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajon, Yamuna D Paila, Bethany Girard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 YearsErick F Mayer, Ann R Falsey, Rebecca Clark, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
Human Vaccines & Immunotherapeutics|April 2, 2025
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titersBoris Kandinov, Mieke Soens, Wenmei Huang, et al.
The Lancet. Infectious Diseases|November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trialJaya Goswami, Jose F Cardona, Denise C Hsu, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
The Lancet. Infectious Diseases|March 22, 2024
Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trialAvika Dixit, Richard Bennett, Kashif Ali, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trialMatteo S Carlino, Georgina V Long, Dirk Schadendorf, et al.
Lancet (London, England)|August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
Nature Communications|August 23, 2023
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
The New England Journal of Medicine|September 16, 2022
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Spyros Chalkias, Charles Harper, Keith Vrbicky, et al.
Nature Medicine|February 11, 2022
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajon, Yamuna D Paila, Bethany Girard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 YearsErick F Mayer, Ann R Falsey, Rebecca Clark, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
Human Vaccines & Immunotherapeutics|April 2, 2025
An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titersBoris Kandinov, Mieke Soens, Wenmei Huang, et al.
The Lancet. Infectious Diseases|November 28, 2024
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trialJaya Goswami, Jose F Cardona, Denise C Hsu, et al.
Pageof 10